Compass Therapeutics (CMPX) Non Operating Income (2019 - 2026)

Compass Therapeutics has disclosed Non Operating Income across 8 years of filings, most recently posting $2.0 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $2.0 million, up 48.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 million (up 6.03% YoY), and the FY2025 annual result was $6.4 million, down 12.41% from the prior year.
• Non Operating Income came in at $2.0 million for Q1 2026 at Compass Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.3 million in Q4 2025 to a low of $20000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $1.8 million (2024), against an average of $1.5 million.
• Across the five-year window, Non Operating Income jumped 18385.71% in 2022 and slumped 39.82% in 2025, its largest moves.
• Compass Therapeutics' Non Operating Income stood at $1.3 million in 2022, then surged by 52.86% to $2.0 million in 2023, then slipped by 22.09% to $1.5 million in 2024, then soared by 47.57% to $2.3 million in 2025, then slipped by 12.84% to $2.0 million in 2026.
• The last three Non Operating Income figures came in at $2.0 million (Q1 2026), $2.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.